The information is contained in the first edition of the bulletin on the effectiveness of vaccines against covid-19 in the Brazilian population, from the Vigivac project by Fiocruz, published on the 9th.
ButanVac will be produced at the Butantan factory where flu vaccines are made—a production that has already come to an end this year. ButanVac will be fully manufactured in São Paulo, with no imported supplies necessary.
In March, 19.3 million doses have been delivered. By the end of April, the total amount of vaccines provided by Butantan will have reached 46 million.
It is efficient against the British B.1.1.7, the South African B.1.351, and Brazil’s B.1.1.28, of which are derived variants P.1, from Manaus, and P.2, from Rio de Janeiro.